HIMS Stock Forecast & Price Target

Hims & Hers Health is poised for significant growth, projecting nearly $1 billion in international revenue by FY30, representing a tenfold increase from an anticipated $50 million in FY25, driven by expanded treatment options and market entry. The company expects its core U.S. revenue to grow approximately 21% annually, with a substantial portion of this growth attributed to a rising subscriber base and enhanced revenue per subscriber through personalization and cross-selling strategies. With over 2 million subscribers and a robust telehealth platform, Hims & Hers is well-positioned to capitalize on the increasing trend towards private healthcare adoption.

Hims & Hers Health has experienced a notable decline of over 20% in its stock price since late July, despite having more than doubled year-to-date, primarily due to concerns surrounding slowing core growth. The company faces several challenges, including sluggish adoption of personalized treatments, regulatory pressures in a highly regulated healthcare industry, and intensifying competition within the digital health space, all of which could hinder its ability to sustain revenue expansion. Additionally, Hims & Hers' reliance on consumer spending makes it vulnerable to economic downturns that could reduce disposable income for its direct-to-consumer healthcare subscriptions.